CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers. Under some conditions, TIM-3 expression has also been shown to be stimulatory. Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), is being targeted for cancer immunotherapy, it is important to identify the circumstances under which TIM-3 can inhibit and activate T-cell responses. Here we show that TIM-3 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), another well-known molecule expressed on activated T cells and involved in T-cell inhibition. Biochemical, biophysical and X-ray crystallography studies show that the membrane-distal immunoglobulin-variable (IgV)-like amino-terminal domain of each is crucial to these interactions. The presence of CEACAM1 endows TIM-3 with inhibitory function. CEACAM1 facilitates the maturation and cell surface expression of TIM-3 by forming a heterodimeric interaction in cis through the highly related membrane-distal N-terminal domains of each molecule. CEACAM1 and TIM-3 also bind in trans through their N-terminal domains. Both cis and trans interactions between CEACAM1 and TIM-3 determine the tolerance-inducing function of TIM-3. In a mouse adoptive transfer colitis model, CEACAM1-deficient T cells are hyper-inflammatory with reduced cell surface expression of TIM-3 and regulatory cytokines, and this is restored by T-cell-specific CEACAM1 expression. During chronic viral infection and in a tumour environment, CEACAM1 and TIM-3 mark exhausted T cells. Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models. Thus, CEACAM1 serves as a heterophilic ligand for TIM-3 that is required for its ability to mediate T-cell inhibition, and this interaction has a crucial role in regulating autoimmunity and anti-tumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interaction between TIM-3 and its four ligands (galectin 9, high mobility group protein B1, phosphatidyl serine, and carcinoembryonic antigen cell adhesion molecule 1) can diminish anti-tumor immunity through a variety of mechanisms including inducing CD8+ T cell death and exhaustion (Huang et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Huang et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We stimulated primary microglia with galectin-9 and CEACAM1, both of which mediate TIM-3 function in T cells by phosphorylating Y256 and Y263 residues34,35. This treatment had no effect on pSMAD2 expression”
From Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease (2025) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · cited 2×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · cited 4×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
InfluentialHaploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Multiple Sequence Alignment Using ClustalW and ClustalX
Thompson, J. D., Gibson, T. J., & Higgins, D. G. (2003) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi0203s00 · Cited by 2,971 · cited 1×
“In addition, multiple sequencealignmentswereperformedusingClustalW 45 .”
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM
Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R., & Leslie, A. G. W. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910048675 · Cited by 2,860 · cited 2×
“ThedatawereprocessedwithMosflm 40 andthe CCP 4softwaresuite 41 .”
Direct observation of individual endogenous protein complexes in situ by proximity ligation
Söderberg, O., Gullberg, M., Jarvius, M., Ridderstråle, K., Leuchowius, K.-J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.-G., et al. (2006) · Nature Methods · doi:10.1038/nmeth947 · Cited by 2,419
Cited by
Items 201–300 of 718
Helfrich, I., & Singer, B. B. (2019) · Cancers · doi:10.3390/cancers11030356 · Cited by 59
“Although a biochemical heterodimer of TIM‐3 and CEACAM1 was stated when first reported, it has since been accepted that the molecular co‐localization of these proteins occurs due to the formation of an immunological synapse in T‐cells [56,58,59].”
BackgroundInfluentialIdentification and characterization of M6903, an antagonistic anti–TIM-3 monoclonal antibody
Zhang, D., Jiang, F., Zaynagetdinov, R., Huang, H., Sood, V. D., Wang, H., Zhao, X., Jenkins, M. H., Ji, Q., Wang, Y., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1744921 · Cited by 49
“(2015) demonstrated through mutational analysis that residues E62, R111, and D120 contribute significantly to that interaction.(7) Our structure reveals that these residues interact closely with the heavy chain of M6903, and D120 forms direct hydrogen bonds to the paratope (Figure 2d).”
BackgroundDevillier, R., Chrétien, A.-S., Pagliardini, T., Salem, N., Blaise, D., & Olive, D. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0920-198rr · Cited by 50
Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
Lee, H., da Silva, I. P., Palendira, U., Scolyer, R. A., Long, G. V., & Wilmott, J. S. (2021) · Cancers · doi:10.3390/cancers13061363 · Cited by 49
“TIM-3 is another inhibitory receptor that binds to galectin-9 [231], phosphatidylserine on apoptotic cells [232], high mobility group box 1 [233] and carcinoembryonic antigenrelated cell adhesion molecule 1 [234].”
BackgroundThe role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis
Rueckschloss, U., Küerten, S., & Ergün, S. (2016) · Histochemistry and Cell Biology · doi:10.1007/s00418-016-1505-9 · Cited by 47
Yu, S., Ren, X., Meng, F., Guo, X., Tao, J., Zhang, W., Liu, Z., Fu, R., & Li, L. (2022) · Immunology · doi:10.1111/imm.13488 · Cited by 46
“It mediates the immunosuppressive effects of TIM3 through binding to the CC’ and FG loops of TIM3 or TIM3 intracellularly [15].”
BackgroundKöhler, N., Ruess, D. A., Kesselring, R., & Zeiser, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634435 · Cited by 48
Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
Zhai, Y., Moosavi, R., & Chen, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645699 · Cited by 49
“There are at least four ligands identified for TIM-3: Galectin-9 (Gal-9), Phosphatidyl serine (61) high mobility group protein B1 (62) and Ceacam-1 (63).”
BackgroundErratum: Corrigendum: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Huang, Y., Zhu, C. Y., Kondo, Y., Anderson, A. C., Gandhi, A. K., Russell, A., Dougan, S. K., Petersen, B., Melum, E., Pertel, T., et al. (2016) · Nature · doi:10.1038/nature17421 · Cited by 43
Self-citationNF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges
Guo, Q. H., Jin, Y., Lin, M., Zeng, C., & Zhang, J. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122684 · Cited by 57
Zhang, L., Wang, J., Wei, F., Wang, K., Sun, Q., Yang, F., Jin, H., Zheng, Y., Zhao, H., Wang, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9871 · Cited by 44
“Of interest, CEACAM1, which forms a heterodimeric interaction with TIM-3 [20], was upregulated simultaneously (Figure 3A, 3B, 3C, and Figure S2).”
InfluentialBlaeschke, F., Willier, S. M., Stenger, D., Lepenies, M., Horstmann, M. A., Escherich, G., Zimmermann, M., Ringeling, F. R., Canzar, S., Kaeuferle, T., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0793-1 · Cited by 56
Cong, Y., Cui, Y., Zhu, S., Cao, J., Zou, H., Martin, T. A., Qiao, G., Jiang, W. G., & Yu, Z. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.05.02 · Cited by 48
“molecule-3 (Tim-3), also known as hepatitis A virus cellular receptor 2 (HAVCR2), is a negative immune checkpoint molecule expressed on a variety of immune cells including T-cells (4), dendritic cells (5) and macrophages (6).”
BackgroundPfeifhofer‐Obermair, C., Tymoszuk, P., Nairz, M., Schroll, A., Klais, G., Demetz, E., Engl, S., Brigo, N., & Weiß, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637809 · Cited by 45
The immunosuppressive landscape in tumor microenvironment
Liu, W., Zhou, H., Lai, W., Hu, C., Xu, R., Gu, P., Luo, M., Zhang, R., & Li, G. (2024) · Immunologic Research · doi:10.1007/s12026-024-09483-8 · Cited by 48
“CEACAM1 forms a heterodimer with TIM-3 via its N-terminal domain, promoting the stable expression of TIM-3 and resulting in TIM-3 mediated T cell exhaustion [25].”
Zhu, C., Dixon, K. O., Newcomer, K., Gu, G., Xiao, S., Zaghouani, S., Schramm, M. A., Wang, C., Zhang, H., Goto, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd2710 · Cited by 40
Self-citationOn the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment
Tundo, G. R., Sbardella, D., Lacal, P. M., Graziani, G., & Marini, S. (2019) · Chemotherapy · doi:10.1159/000500902 · Cited by 44
Potential influences of complement factor H in autoimmune inflammatory and thrombotic disorders
Ferluga, J., Kouser, L., Murugaiah, V., Sim, R. B., & Kishore, U. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.01.015 · Cited by 45
“Recently, it has been indicated that such Th1/Tim-3 tolerance is itself regulated through heterodimerization with the carcinoembryonic antigen cell adhesion molecule-1 (CEACAM-1) (Huang et al. 2015).”
BackgroundKey questions about the checkpoint blockade-are microRNAs an answer?
Dragomir, M. P., Chen, B., Fu, X., & George, A. C. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0006 · Cited by 42
Călinescu, A., Turcu, G., Nedelcu, R., Brînzea, A., Hodorogea, A., Antohe, M., Diaconu, C. C., Bleoţu, C., Pirici, D., Jilaveanu, L. B., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/7169081 · Cited by 41
“CRC cancer mouse models demonstrate that coblockade of CEACAM1 and TIM-3 leads to enhancement of antitumor immune responses and improved elimination of tumors [18].”
BackgroundInfluentialBiomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
Yiong, C. S., Lin, T. P., Lim, V., Toh, T. B., & Yang, V. S. (2023) · Biomarker Research · doi:10.1186/s40364-023-00513-5 · Cited by 46
“CEACAM1 is expressed by T cells [164], DCs [165], monocytes [166] and macrophages [167], and its binding results in TCR signaling inhibition [164].”
BackgroundCheckpoint Inhibitors: Applications for Autoimmunity
Tocheva, A. S., & Mor, A. (2017) · Current Allergy and Asthma Reports · doi:10.1007/s11882-017-0740-z · Cited by 43
Wang, Y., Yang, X., Sun, X., Rong, L., Kang, M., Wu, P., Ji, X., Lin, R., Huang, J., Xue, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1078-8 · Cited by 39
Phosphatidylserine receptor-targeting therapies for the treatment of cancer
Park, M., & Kang, K. W. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01167-4 · Cited by 41
Jafarzadeh, L., Masoumi, E., Mirzaei, H. R., Alishah, K., Fallah-Mehrjardi, K., Khakpoor-Koosheh, M., Rostamian, H., Noorbakhsh, F., & Hadjati, J. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.06.007 · Cited by 40
Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches
Batista-Duharte, A., Hassouneh, F., Álvarez-Heredia, P., Pera, A., & Solana, R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081721 · Cited by 39
“In addition, TIM-3 induces peripheral immune tolerance [50,51] and its expression is a sign of exhaustion and apoptosis in T cells during chronic infections [52].”
BackgroundWang, J., Wang, Y., Jiang, X., Xu, M., Wang, M., Wang, R., Zheng, B., Chen, M., Qi, K., & Long, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216758 · Cited by 44
The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells
Zhang, J., Wang, L., Guo, H., Kong, S., Li, W., He, Q., Ding, L., & Yang, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107458 · Cited by 42
The role of immune regulatory molecules in multiple sclerosis
Afshar, B., Khalifehzadeh-Esfahani, Z., Seyfizadeh, N., Danbaran, G. R., Hemmatzadeh, M., & Mohammadi, H. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.577061 · Cited by 39
Modulation of Immune Checkpoints by Chemotherapy in Human Colorectal Liver Metastases
Jabbari, N., Kenerson, H. L., Lausted, C. G., Yan, X. S., Meng, C., Sullivan, K. M., Baloni, P., Bergey, D. E., Pillarisetty, V. G., Hood, L., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100160 · Cited by 38
Unraveling the Role of Immune Checkpoints in Leishmaniasis
Silva, R. D. F. E., & von Stebut, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.620144 · Cited by 49
Wen, L., Lu, H., Li, Q., Li, Q., Wen, S., Wang, D., Wang, X., Fang, J., Cui, J., Cheng, B., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1185-0 · Cited by 39
TIM-3 and CEACAM1 are Prognostic Factors in Head and Neck Squamous Cell Carcinoma
Yang, F., Zeng, Z., Li, J., Ren, X., & Wei, F. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.619765 · Cited by 36
Bailly, C., Thuru, X., Goossens, L., & Goossens, J. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115445 · Cited by 41
Conway, J., Jong, E. N. D., White, A. J., Dugan, B., Rees, N. P., Parnell, S. M., Lamberte, L. E., Sharma‐Oates, A., Sullivan, J., Mauro, C., et al. (2024) · Aging Cell · doi:10.1111/acel.14401 · Cited by 46
Zhuo, Y., Yang, J., Moremen, K. W., & Prestegard, J. H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.740050 · Cited by 37
“The glycosylated versions of CEACAM1-IgV were expressed in mammalian (HEK293) cell cultures producing large and complex wild type glycans (FreeStyleTM 293-”
BackgroundInfluentialSLC7A7 is a prognostic biomarker correlated with immune infiltrates in non-small cell lung cancer
Dai, W., Feng, J., Hu, X., Chen, Y., Gu, Q., Gong, W., Feng, T., & Wu, J. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01781-7 · Cited by 40
“TIM-3, an important surface protein on exhausted T cells [27], was highly correlated with SLC7A7 expression in NSCLC.”
BackgroundTIM‐3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways
Kikushige, Y. (2021) · Cancer Science · doi:10.1111/cas.15042 · Cited by 39
SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects
Rosenbaum, S. R., Tiago, M., Caksa, S., Capparelli, C., Purwin, T. J., Kumar, G., Glasheen, M. Q., Pomante, D., Kotas, D., Chervoneva, I., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110085 · Cited by 49
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 39
Jantz-Naeem, N., Loschinski, R., Borucki, K., Mitchell-Flack, M., Böttcher, M., Schraven, B. L., Mougiakakos, D., & Kahlfuß, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1060112 · Cited by 38
“TIM3 also works to inhibit T cells via interaction with the ligand Caecam1 (68).”
BackgroundImmune checkpoint inhibitors in infectious disease
King, H. A. D., & Lewin, S. R. (2024) · Immunological Reviews · doi:10.1111/imr.13388 · Cited by 43
Extracellular galectins as controllers of cytokines in hematological cancer
Gordón‐Alonso, M., Bruger, A. M., & van der Bruggen, P. (2018) · Blood · doi:10.1182/blood-2018-04-846014 · Cited by 36
Martinez, M. C., Kim, S., Jean, N. S., O’Brien, S., Lian, L., Sun, J., Verona, R. I., & Moon, E. K. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1873607 · Cited by 37
“TIM3 traditionally is thought of as a T cell suppressing receptor(15) but more recently has been shown to stimulate T cells in certain conditions.(16) TIM3 is also involved in macrophage activation(17) and is expressed on Treg cells.”
BackgroundRietz, T. A., Teuscher, K. B., Mills, J. J., Gogliotti, R. D., Lepovitz, L. T., Scaggs, W. R., Yoshida, K., Luong, K., Lee, T., & Fesik, S. W. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01336 · Cited by 37
Photophosphatidylserine Guides Natural Killer Cell Photoimmunotherapy via Tim-3
Yang, X., Li, M., Qin, X., Tan, S., Du, L., Ma, C., & Li, M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c11498 · Cited by 37
Su, H., Xie, H., Dai, C., Ren, Y., She, Y., Xu, L., Chen, D., Xie, D., Zhang, L., Jiang, G., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.009 · Cited by 34
Discovery of New Immune Checkpoints: Family Grows Up
Kong, X. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_4 · Cited by 36
Chen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 38
Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets
Zhou, X., Ren, T., Zan, H., Hua, C., & Guo, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864202 · Cited by 41
“Consequently, TIM-3-mediated T-cell inhibition is promoted by the permissive binding of SH2containing Src kinases and is thus subsequent to the regulation of TCR signaling (62, 63).”
BackgroundTrial Watch: Adoptive cell transfer for oncological indications
Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 35
Helliwell, J. R., McMahon, B., Guss, J. M., & Kroon-Batenburg, L. M. J. (2017) · IUCrJ · doi:10.1107/s2052252517013690 · Cited by 32
“Their news item ‘Structural biology corrections highlight best of the scientific process’ (http:// retractionwatch.com/category/by-subject/basic-life-sciencesretractions/crystallography-retractions) discusses the case of the correction of an earlier publication by the Blumberg group in Nature (Huang et al., 2015) prom…”
BackgroundLiang, Z., & Li, X. (2021) · Autoimmunity · doi:10.1080/08916934.2021.1887148 · Cited by 32
“In regard to T cell exhaustion, the marker gene TIM-3 was closely correlated with ANXA1 expression level, suggesting the underlying mechanism where ANXA1 regulates T cell distribution in CRC [41].”
BackgroundTim-3 Expression Causes NK Cell Dysfunction in Type 2 Diabetes Patients
Wang, H., Cao, K., Liu, S., Xu, Y., & Tang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.852436 · Cited by 37
“Galectin-9/Tim-3 Pathway Blockade Restores NK Cell Function It has been reported that Tim-3 exerts inhibitory function in T cells by interacting with Galectin-9, while the reports on CD66a/ Tim-3 interaction remain conflicting (16, 28).”
BackgroundTherapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer
Fattori, S., Roux, H., Connen, E., Robert, L., Gorvel, L., Roy, A. L., Houacine, J., Foussat, A., Chrétien, A.-S., & Olive, D. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0654 · Cited by 37
Abdeladhim, M., Karnell, J. L., & Rieder, S. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1033705 · Cited by 40
TIM‐3 and CEACAM1 do not interact in cis and in trans
Linhares, A. D. S., Kellner, F., Jutz, S., Zlabinger, G. J., Gabius, H., Huppa, J. B., Leitner, J. M., & Steinberger, P. (2020) · European Journal of Immunology · doi:10.1002/eji.201948400 · Cited by 37
“According to Huang et al., CEA-CAM1 promoted surface expression of TIM-3 and these two receptors were extensively coexpressed on human and mouse T cells [28].”
InfluentialImmune checkpoint receptors in cancer: redundant by design?
Li, J., Ni, L., & Dong, C. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.001 · Cited by 33
Li, J., Liu, X., Duan, Y., Liu, Y., Wang, H., Lian, S., Zhuang, G., & Fan, Y. (2017) · Medical Science Monitor · doi:10.12659/msm.903098 · Cited by 30
“Interestingly, in a recent study, CEACAM1 has been identified as a novel heterophilic ligand for Tim-3, and it can regulate Tim-3-mediated immune tolerance and exhaustion of T cells [30].”
BackgroundInfluentialLiu, X., Xu, Q., Li, Z., & Xiong, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-77657-z · Cited by 40
Riva, A., Palma, E., Devshi, D., Corrigall, D., Adams, H., Heaton, N. D., Menon, K., Preziosi, M., Zamalloa, A., Miquel, R., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.632502 · Cited by 33
TIM3+ cells in gastric cancer: clinical correlates and association with immune context
Chen, K., Gu, Y., Cao, Y., Fang, H., Lv, K., Liu, X., He, X., Wang, J., Lin, C., Liu, H., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01607-3 · Cited by 33
“As an immunoregulatory molecule, TIM3 mediates T cell exhaustion by binding to its ligands, galectin-9 [15], carcinoembryonic antigenrelated cell adhesion molecule 1 [16] and high-mobility group protein B1 [17].”
BackgroundLiu, Y., Zhang, Z., Wang, S., Fu, S., Cheng, X., Chen, R., & Sun, T. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108900 · Cited by 35
Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
Yu, L., Sun, M., Zhang, Q., Zhou, Q., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982026 · Cited by 33
“Coexpressed with carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), the maturation and cell surface expression of Tim-3 is regulated by CEACAM1 by forming a heterodimer to mediate immune tolerance and T cell exhaustion (50).”
BackgroundCutting Edge: Anti–TIM-3 Treatment Exacerbates Pulmonary Inflammation and Fibrosis in Mice
Isshiki, T., Akiba, H., NAKAYAMA, M., Harada, N., Okumura, K., Homma, S. A., & Miyake, S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700059 · Cited by 33
“In addition, a recent study indicated that the blockade of carcinoembryonic Ag-related cell adhesion molecule 1–TIM-3 interactions enhanced antitumor immune responses with the improved elimination of tumors in mouse colorectal cancer models (18).”
BackgroundGravina, A., Tediashvili, G., Zheng, Y., Iwabuchi, K. A., Peyrot, S. M., Roodsari, S. Z., Gargiulo, L., Kaneko, S., Osawa, M., Schrepfer, S., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.10.003 · Cited by 32
“22 Numerous ligands have been proposed for TIM3, including galectin-9, phosphatidylserine, HMGB1, and CEACAM1, and although it is widely regarded as an inhibitory receptor, under some circumstances TIM3 may serve as an activating receptor.”
Lu, T., Liu, Y., Huang, X., Sun, S., Xu, H., Jin, A., Wang, X., Gao, X., Liu, J., Zhu, Y., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202303681 · Cited by 32
Franzese, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312848 · Cited by 32
Melanoma: oncogenic drivers and the immune system.
Karachaliou, N., Pilotto, S., Teixidó, C., Viteri, S., González‐Cao, M., Riso, A. A., Morales-Espinosa, D., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Santarpía, M., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.06 · Cited by 34
“Recent evidence demonstrated that TIM3 is usually co-expressed and interacts with CEACAM1 and that this binding is crucial for TIM3 regulatory effects (215).”
BackgroundKammerer, R., Mansfeld, M., Hänske, J., Mißbach, S., He, X., Köllner, B., Mouchantat, S., & Zimmermann, W. (2017) · BMC Genomics · doi:10.1186/s12864-017-4106-7 · Cited by 30
“In primates and rodents the CEACAM1-related genes belong either to the CEA-related cell adhesion molecule (CEACAM) or the pregnancy-specific glycoprotein (PSG) subgroups.”
BackgroundFrom T cell “exhaustion” to anti-cancer immunity
Verdeil, G., Marraco, S. A. F., Murray, T. J., & Speiser, D. E. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.007 · Cited by 33
A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy
Peng, S., & Bao, Y. (2022) · Annals of Blood · doi:10.21037/aob-21-3 · Cited by 33
“Recent studies have shown that TIM-3 is co-expressed with and interacts with CECAM1.”
BackgroundInfluentialLi, Y. M., Shi, Y., Li, Y., Yan, L., Tang, J. T., Bai, Y. J., Wu, X. J., Dai, B., Zou, Y., & Wang, L. L. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.01.008 · Cited by 29
Elia, A. R., Caputo, S., & Bellone, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01786 · Cited by 32
“Ceacam-1, an additional TIM-3 ligand, is co-expressed on exhausted T cells, can bind TIM-3 both in cis and trans, and both interactions drive the inhibitory function of TIM-3 (66).”
BackgroundChen, Y., Chen, W., Dai, X., Zhang, C., Zhang, Q., & Lu, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106798 · Cited by 32
Roussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 34
“…and (IgV)-like which binds and Y272 ) and the myeloid cells, on tumor cells/T cell lines/NK cells/myeloid cells (DCs, monocytes, and macrophages) [167–169], phosphatidylserine [170] on apoptotic cells, and extracellular high-mobility group box 1 (HMGB1) [171]. impairing protein located of…”
FCGR1A Serves as a Novel Biomarker and Correlates With Immune Infiltration in Four Cancer Types
Xu, J.-L., & Guo, Y. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.581615 · Cited by 26
“TIM-3 is a vital surface protein on T cell exhaustion (Huang et al., 2015) and is highly correlated with FCGR1A expression in CESC and SKCM.”
BackgroundChen, Z., Zhuo, S., He, G., Tang, J., Hao, W., Gao, W., Yang, K., & Xu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.721897 · Cited by 29
“…[TIGIT (Manieri et al., 2017), CEACAM1 (Huang et al., 2015), CTLA4 (Krummel and Allison, 1996; Postow et al., 2015), LAG3 (Ruffo et al., 2019), PD1 (Ishida et al., 1992; Postow et al., 2015), PD-L1 (Postow et al., 2015), and TIM3 (Huang et al., 2015)] were highly expressed in the high-risk subtype…”
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
Ronen, D., Bsoul, A., Lotem, M., Abedat, S., Yarkoni, M., Amir, O., & Asleh, R. (2022) · Vaccines · doi:10.3390/vaccines10040540 · Cited by 29
“T-cell immunoglobulin and mucin-domain containing3 (TIM-3) was shown to reduce CD8 response [71–73] and may be part of the exhausted state of T cells [74].”
BackgroundMetabolic regulation and function of T helper cells in neuroinflammation
Spiljar, M., & Kuchroo, V. K. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00959-z · Cited by 31
Self-citationImmune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells
Kimura, Y., Tsunedomi, R., Yoshimura, K., Matsukuma, S., Shindo, Y., Matsui, H., Tokumitsu, Y., Yoshida, S., Iida, M., Suzuki, N., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12220-w · Cited by 27
Lin, Y., Cai, B., Li, Y., Wang, M., An, Y., Deng, R., Li, D., Wang, L., Xu, H., Gao, X., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16044 · Cited by 26
“Hospital duration (d) 41 (10-50) 7 (2-18) <0.”
Wang, Q., Wang, Z., Zhang, Z., Zhang, W., Zhang, M., Shen, Z., Ye, Y., Jiang, K., & Wang, S. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.02.13 · Cited by 29
“Additionally, the glycolysis pathway was most highly expressed in cluster 2 among the three clusters, and a related gene, PKM, was also highly expressed (32).”
BackgroundSingle-cell immune checkpoint landscape of PBMCs stimulated with Candida albicans
Deng, W., Su, Z., Liang, P., Ma, Y., Liu, Y., Zhang, K., Zhang, Y., Liang, T., Shao, J., Liu, X., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1942228 · Cited by 29
“Ligands combined with Tim-3/HAVCR2 are Galectin-9 (LGALS9) [30], HMGB-1(HMGB1) [31], and CEACAM-1 (CEACAM1) [32].”
Struckmeier, A., Gosau, M., & Smeets, R. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.107145 · Cited by 31
The immunological synapse as a pharmacological target
Finetti, F., & Baldari, C. T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.009 · Cited by 32
Significance of STAT3 in Immune Infiltration and Drug Response in Cancer
Chen, W., Dai, X., Chen, Y., Tian, F., Zhang, Y., Zhang, Q., & Lü, J. (2020) · Biomolecules · doi:10.3390/biom10060834 · Cited by 28
“Infiltrating immune cells include T-cells, B-cells, monocytes, macrophages, natural killer cells, and dendritic cells (DCs).”
BackgroundInfluentialNanotechnologies for enhancing cancer immunotherapy
Yang, J., Wang, C., Shi, S., & Dong, C. (2020) · Nano Research · doi:10.1007/s12274-020-2904-8 · Cited by 27
Chen, H., Zha, J., Tang, R., & Chen, G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110418 · Cited by 31
Gao, Y., Chen, S., Wang, H., Wu, C., An, R., Li, G., Yang, M. J., Zhou, Y., Zhou, Y., Xie, X., et al. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.08.011 · Cited by 28
Xiang, S., Li, S., & Xu, J. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70345 · Cited by 36
“94,97 BAT3 exerts the inhibitory function by being liberated from TIM-3 upon phosphorylation.”
Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance
Zadka, Ł., Grybowski, D. J., & Dzięgiel, P. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00519-3 · Cited by 30
Li, H., Zhou, J., Zhou, L., Zhang, X., Shang, J., Feng, X., Yu, L., Fan, J., Ren, J., Zhang, R., et al. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3558 · Cited by 25
Mestiri, S., El-Ella, D. M. A., Fernandes, Q., Bedhiafi, T., Almoghrabi, S., Akbar, S., Inchakalody, V. P., Assami, L., Anwar, S., Shahab Uddin, M. S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116095 · Cited by 30
Martin, J. N., Ball, L. M., Solomon, T. L., Dewald, A. H., Criss, A. K., & Columbus, L. M. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00124 · Cited by 25
CEACAM1 controls the EMT switch in murine mammary carcinomain vitroandin vivo
Wegwitz, F., Lenfert, E., Gerstel, D., von Ehrenstein, L., Einhoff, J., Schmídt, G., Logsdon, M., Brandner, J. M., Tiegs, G., Beauchemin, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11650 · Cited by 25
Self-citationLiao, P., Wang, H., Tang, Y., Tang, Y.-J., & Liang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02457 · Cited by 29
“The two ligands may therefore play a synergistic role in regulating TIM3 signals (135, 136).”
BackgroundT cell exhaustion and senescence for ovarian cancer immunotherapy
Zhao, J., Wang, Z., Tian, Y., Ning, J., & Ye, H. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.07.001 · Cited by 36
Huang, S., Kang, Y., Liu, T., Xiong, Y., Yang, Z., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561968 · Cited by 30
Tipping the balance: inhibitory checkpoints in intestinal homeostasis
Joosse, M. E., Nederlof, I., Walker, L. S. K., & Samsom, J. N. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0113-5 · Cited by 26
Metadata
- Authors
- Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., Clayton, K. L., Raab, M., Chen, Q., Beauchemin, N., Yazaki, P. J., Pyzik, M., Ostrowski, M. A., Glickman, J. N., Rudd, C. E., Ploegh, H. L., Franke, A., Petsko, G. A., Kuchroo, V. K., & Blumberg, R. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Brandeis University (US)
- Massachusetts Institute of Technology (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Oslo University Hospital (NO)
- University of Toronto (CA)
- University of Cambridge (GB)
- Sichuan University (CN)
- McGill University (CA)
- City Of Hope National Medical Center (US)
- St. Michael's Hospital (CA)
- Corresponding author
- Blumberg, Richard S.
- ORCID
- Venue
- Nature
- Published
- 2014-10-26
- Volume
- 517
- Issue
- 7534
- Pages
- 386-390
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4297519
- OpenAlex
- W2122730216
- Cited by
- 717
- References
- 58
- Citations by year
- 2026: 44 · 2025: 72 · 2024: 85 · 2023: 82 · 2022: 71 · 2021: 82 · 2020: 76 · 2019: 51 · 2018: 47 · 2017: 40 · 2016: 38 · 2015: 28
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR001102)
- National Institute of General Medical Sciences (R01GM032415, T32GM007122, GM-32415, R37GM032415, P41GM111244, R01GM026788)
- National Institute of Allergy and Infectious Diseases (AI 056299, P01AI073748, AI039671, AI073748, P01AI056299, P01AI039671)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK044319, DK0034854, R01DK053056, DK088199, DK053056, R56DK053056, DK051362, R37DK044319, R01DK051362, P30DK034854, R01DK044319, R01DK088199)
- National Institute of Neurological Disorders and Stroke (NS045937, R01NS045937)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- TIM-3, T cell exhaustion, immune tolerance, immune checkpoint, T cell co-inhibition, T cell costimulation, colorectal cancer, antitumor immunity, T cell receptor signaling
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Cell Line, Disease Models, Animal, Female, Humans, Immune Tolerance, Inflammation, Ligands, Male, Membrane Proteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Models, Molecular, Mucous Membrane, Protein Conformation, Receptors, Virus, T-Lymphocytes, Colorectal Neoplasms, Autoimmunity, Antigens, CD, Cell Adhesion Molecules, Mice, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.